JP2022550345A5 - - Google Patents
Info
- Publication number
- JP2022550345A5 JP2022550345A5 JP2022519226A JP2022519226A JP2022550345A5 JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5 JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022519226 A JP2022519226 A JP 2022519226A JP 2022550345 A5 JP2022550345 A5 JP 2022550345A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- amino acid
- signaling molecule
- cancer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025259819A JP2026048868A (ja) | 2019-09-26 | 2025-12-17 | Pd-l1標的化キメラタンパク質及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906447P | 2019-09-26 | 2019-09-26 | |
| US62/906,447 | 2019-09-26 | ||
| PCT/US2020/052764 WO2021062184A1 (en) | 2019-09-26 | 2020-09-25 | Pd-l1 targeted chimeric proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025259819A Division JP2026048868A (ja) | 2019-09-26 | 2025-12-17 | Pd-l1標的化キメラタンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550345A JP2022550345A (ja) | 2022-12-01 |
| JP2022550345A5 true JP2022550345A5 (cg-RX-API-DMAC7.html) | 2023-10-31 |
| JP7793511B2 JP7793511B2 (ja) | 2026-01-05 |
Family
ID=75166458
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519226A Active JP7793511B2 (ja) | 2019-09-26 | 2020-09-25 | Pd-l1標的化キメラタンパク質及びその使用 |
| JP2025259819A Pending JP2026048868A (ja) | 2019-09-26 | 2025-12-17 | Pd-l1標的化キメラタンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025259819A Pending JP2026048868A (ja) | 2019-09-26 | 2025-12-17 | Pd-l1標的化キメラタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230002493A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4034565A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7793511B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114761430A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020353660A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3151928A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021062184A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3890773A4 (en) * | 2018-11-08 | 2022-11-09 | Orionis Biosciences, Inc. | MODULATION OF DENDRITIC CELL LINES |
| JP2024527571A (ja) * | 2021-07-08 | 2024-07-25 | オリオンズ バイオサイエンス インコーポレイテッド | インターロイキン-1アルファキメラタンパク質 |
| US12559576B2 (en) | 2021-11-11 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | CD20-PD1 binding molecules and methods of use thereof |
| JP2026525313A (ja) * | 2023-07-14 | 2026-07-29 | オハイオ ステート イノベーション ファウンデーション | 抗体-薬物コンジュゲート、並びにそのリンカー及び使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101704734B1 (ko) * | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CA2712432C (en) * | 2008-01-29 | 2018-09-25 | Ablynx N.V. | Methods to stabilize single variable domains |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US20140079691A1 (en) * | 2012-09-20 | 2014-03-20 | Anaptysbio, Inc. | Thermostable antibody framework regions |
| CN106999583A (zh) * | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CN109071632B (zh) * | 2016-02-05 | 2022-12-30 | 奥里尼斯生物科学私人有限公司 | 靶向性治疗剂及其用途 |
| US11661455B2 (en) * | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| AU2017384528A1 (en) * | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
| FI3596116T3 (fi) * | 2017-03-16 | 2023-11-09 | Alpine Immune Sciences Inc | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä |
| US11780930B2 (en) * | 2017-06-08 | 2023-10-10 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| GB201710973D0 (en) * | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| EP3664829A4 (en) * | 2017-08-09 | 2021-05-05 | Orionis Biosciences, Inc. | LIAISON OFFICERS AT PD-1 AND PD-L1 |
| US12564632B2 (en) * | 2017-11-08 | 2026-03-03 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | Conjugates of biomolecule and use thereof |
| JP7689079B2 (ja) * | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ,インコーポレイテッド | 治療用インターフェロンアルファ1タンパク質 |
-
2020
- 2020-09-25 CN CN202080082078.6A patent/CN114761430A/zh active Pending
- 2020-09-25 JP JP2022519226A patent/JP7793511B2/ja active Active
- 2020-09-25 EP EP20867685.8A patent/EP4034565A4/en active Pending
- 2020-09-25 CA CA3151928A patent/CA3151928A1/en active Pending
- 2020-09-25 US US17/763,344 patent/US20230002493A1/en active Pending
- 2020-09-25 AU AU2020353660A patent/AU2020353660A1/en active Pending
- 2020-09-25 WO PCT/US2020/052764 patent/WO2021062184A1/en not_active Ceased
-
2025
- 2025-12-17 JP JP2025259819A patent/JP2026048868A/ja active Pending